Under the agreement, AMRI will combine its discovery and development capabilities with Proteros’ structural biology services to offer better services to the life sciences industry worldwide.
Proteros is a provider of protein crystallization and X-ray structural analysis services, while AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for healthcare companies.
Proteros CEO Torsten Neuefeind said he looks forward to the new opportunities they can provide to the life science community as a result of this alliance with AMRI.